Kuros Biosciences AG

Detailed Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.